Mauricio Sarmiento M., Pablo Bertín Cortés-Monroy, Pablo Lira Vergara, María Alejandra Rodríguez Ingles, María José García-Rodríguez, Pablo Ramírez Villanueva, Mauricio Ocqueteau
Thrombotic thrombocytopenic purpura, an immune/non-immune thrombotic microangiopathy (TTP/TMA) is associated with high morbidity and mortality, even with appropriate treatment. In patients refractory to standard treatment with plasmapheresis there is no certainty about the best therapeutic strategy. This report shows our experience in eight refractory patients who survived after treatment with rituximab.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados